26 completed, 9 terminated, 7 recruiting, 7 unknown. 54 Phase 2, 14 Phase 1, 6 Phase 3.
Follow Muscle Hypertonia: new trials by email Literature Review of Muscle Hypertonia trials Research Report on Muscle Hypertonia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Phase IIb Study of Nabiximols for Spasticity Due to Neuromyelitis Optica Spectrum Disorders Nabiximols, Placebo - NMO Spectrum Disorder, Spasticity, Muscle | Phase 2 | Withdrawn | Michael, Levy M.D.,Ph.D. | 2026-12-31 | 2025-07-16 | |
| Extracorporeal Shockwave Therapy as an Additional Treatment for Spasticity Secondary to Spinal Cord Injury Focused extracorporeal shockwave therapy, Botulinum toxin, Sham - Spinal Cord Injury, Spasticity | Phase 2 | Recruiting | Kessler Foundation | 30 | 2026-09-21 | 2026-11-04 |
| A Pilot Study to Evaluate the Efficacy, Safety and Tolerability of BMS-986368, a FAAH/MAGL Inhibitor, in Participants With Post-Stroke Spasticity (The STIPS Study) Administration of BMS-986368, Placebo - Post-Stroke Spasticity | Phase 2 | Recruiting | Alberto Esquenazi | 42 | 2026-09-02 | 2026-10-01 |
| The Use of Photobiomodulation in the Treatment of Spasticity After Stroke. Photobiomodulation Therapy, Placebo PBM, Standard Multidisciplinary Rehabilitation Program for Spasticity - Stroke, Spasticity | Phase 1 / Phase 2 | Recruiting | University of Nove de Julho | 42 | 2026-08-28 | 2026-09-01 |
| Virtual tES Device Treatment for Parkinson's Disease Motor Symptoms Transcranial Electrical Stimulation Device - PARKINSON DISEASE (Disorder) | Phase 1 / Phase 2 | Recruiting | U: The Mind Company | 30 | 2026-01-01 | 2026-01-27 |
| Safety and Efficacy of AAV9/AP4B1 (BFB-101) For Patients With AP4B1-related Hereditary Spastic Paraplegia Type 47 (SPG47) BFB-101 (AAV9-CBh-AP4B1) - HSP, Hereditary Spastic Paraplegia | Phase 1 / Phase 2 | Not yet recruiting | BlackfinBio Ltd | 5 | 2025-08-01 | 2025-04-28 |
| A Study to Evaluate the Efficacy, Safety and Tolerability of BMS-986368 in Participants With Multiple Sclerosis Spasticity BMS-986368, Placebo - Multiple Sclerosis Spasticity | Phase 2 | Recruiting | Celgene | 200 | 2025-06-05 | 2026-10-27 |
| Lateral Cord Magnetic Stimulation For Refractory Spastic Cerebral Palsy Magnetic Spinal Stimulation - Spastic Cerebral Palsy, Dysarthria | Phase 2 / Phase 3 | Unknown | Sociedad Argenttina de Neuromodulación | 20 | 2024-11-18 | 2023-11-21 |
| Therapeutic Photobiomodulation and Tretament of Spasticity Photobiomodulation, Institution's Standard Physiotherapy, Photobiomodulation Placebo - Muscle Spasticity, Cerebral Palsy | Phase 2 / Phase 3 | Completed | University of Nove de Julho | 12 | 2023-08-15 | 2026-05-01 |
| Melpida: Recombinant Adeno-associated Virus (Serotype 9) Encoding a Codon Optimized Human AP4M1 Transgene (hAP4M1opt) MELPIDA - Spasticity, Muscle, Microcephaly | Phase 1 / Phase 2 | Recruiting | Elpida Therapeutics SPC | 4 | 2023-02-15 | 2026-07-08 |
| ADX-629 Therapy for Sjogren-Larsson Syndrome ADX-629 - Sjogren-Larsson Syndrome | Phase 1 / Phase 2 | Completed | University of Nebraska | 8 | 2023-01-02 | 2026-05-05 |
| INcobotulinumtoxina in ChIldren Upper and Lower Limb sPasticITy (INCIPIT) IncobotulinumtoxinA 100 UNT [Xeomin] - Spastic Cerebral Palsy | Phase 2 | Unknown | Universita di Verona | 30 | 2022-06-01 | 2022-04-22 |
| Phase II Study to Assess Safety, Pharmacokinetics and Efficacy of SL-1002 for Limb Spasticity SL-1002, Placebo - Spasticity | Phase 2 | Unknown | Saol Therapeutics Inc | 32 | 2022-04-22 | 2023-09-06 |
| Efficacy and Safety Study of MYOBLOC® in the Treatment of Adult Upper Limb Spasticity Phase 2; Low Dose MYOBLOC (10,000 Units), Phase 2; High Dose MYOBLOC (20,000 Units), Phase 2; Placebo - Spasticity, Cerebrovascular Accident | Phase 2 / Phase 3 | Terminated | Solstice Neurosciences, LLC, a subsidiary of MDD US Operations, LLC | 32 | 2021-11-02 | 2026-05-27 |
| Peripheral Modulation of Muscle Stiffness and Spasticity Hyaluronidase, Placebo - Muscle Spasticity | Phase 2 | Active not recruiting | Johns Hopkins University | 56 | 2021-10-11 | 2026-06-30 |
| A Study to Assess the Safety and Efficacy of IPN10200 in Adult Participants With Upper Limb Spasticity. Corabotase, Placebo, Dysport - Spasticity | Phase 1 / Phase 2 | Recruiting | Ipsen | 240 | 2021-04-29 | 2026-07-28 |
| Effects of Baclofen on Presynaptic Inhibition in Humans Baclofen - Spasticity, Muscle, Spinal Cord Injuries | Phase 2 | Withdrawn | University of Alberta | 2020-01-10 | 2024-09-19 | |
| Efficacy and Safety Study of MYOBLOC® in the Treatment of Adult Lower Limb Spasticity Phase 2; Low Dose MYOBLOC (15,000 Units), Phase 2; High Dose MYOBLOC (20,000 Units), Phase 2; Placebo - Spasticity | Phase 2 / Phase 3 | Terminated | Solstice Neurosciences, LLC, a subsidiary of MDD US Operations, LLC | 40 | 2019-12-17 | 2026-05-22 |
| Efficacy of Allogeneic Umbilical Cord Derived Hematopoietic and Mesenchymal Stem Cells in Cerebral Palsy MNC, MSC, Control - Cerebral Palsy, Spastic | Phase 2 | Unknown | Tehran University of Medical Sciences | 108 | 2017-07-23 | 2019-01-08 |
| Efficacy of 5 Weeks of Treatment With BGG492 in Patients With Spasticity Due to Multiple Sclerosis BGG492, Placebo - Muscle Spasticity Due to Multiple Sclerosis | Phase 2 | Withdrawn | Novartis Pharmaceuticals | 2016-10-01 | 2017-04-20 |
Showing 20 of 54. Sign in to see all of them.
Muscle Spasticity (51) · Multiple Sclerosis (14) · Stroke (12) · Cerebral Palsy (11) · Brain Injuries, Traumatic (5) · Marijuana Abuse (5) · Spinal Cord Injuries (4) · Motor Neuron Disease (3) · Amyotrophic Lateral Sclerosis (2) · Hemiplegia (2) · Muscle Rigidity (2) · Pain (2) · Paraplegia (2) · Spastic Paraplegia, Hereditary (2) · Autonomic Nervous System Diseases (1)
Neurologic Manifestations (54) · Neuromuscular Manifestations (54) · Pathological Conditions, Signs and Symptoms (54) · Signs and Symptoms (54) · Muscular Diseases (53) · Musculoskeletal Diseases (53) · Nervous System Diseases (53) · Central Nervous System Diseases (33) · Brain Diseases (26) · Autoimmune Diseases (15) · Autoimmune Diseases of the Nervous System (15) · Demyelinating Autoimmune Diseases, CNS (15) · Demyelinating Diseases (15) · Immune System Diseases (15)
Botulinum Toxins, Type A (5) · nabiximols (4) · Baclofen (3) · Botulinum Toxins (3) · Sodium Chloride (3) · BID protein, human (2) · Clinical Trials, Phase II as Topic (2) · Clinical Trials, Phase III as Topic (2) · Low-Level Light Therapy (2) · Saline Solution (2) · Tolperisone (2) · abobotulinumtoxinA (2) · incobotulinumtoxinA (2) · rimabotulinumtoxinB (2) · tizanidine (2)
Allergan (3) · Acorda Therapeutics (2) · Avigen (2) · Center for Medicinal Cannabis Research (2) · Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) (2) · Solstice Neurosciences, LLC, a subsidiary of MDD US Operations, LLC (2) · Teva GTC (2) · University of Nove de Julho (2) · Alberto Esquenazi (1) · Assistance Publique - Hôpitaux de Paris (1) · Assistive Technology Clinic, Canada (1) · Auxilium Vitae Volterra (1) · BlackfinBio Ltd (1) · Canbex Therapeutics Ltd (1) · Celgene (1)
United States (30) · Canada (7) · Poland (5) · Brazil (4) · Czechia (4) · Hungary (4) · Israel (4) · France (3) · Germany (3) · Italy (3) · Russia (3) · Ukraine (2) · United Kingdom (2) · Argentina (1) · Australia (1)
Arnon Karni, MD (2) · Joseph T Hull, PhD (2) · Alberto Esquenazi, MD (1) · Ali Reza Moaeidi, MD (1) · Amirali Hamidieh, MD (1) · Anahita Majma, MD (1) · Anand D Pandyan, PhD (1) · Anastasia Vishnevetsky, MD, PhD (1) · Ariane Zoll (1) · Carlo Pozzilli, MD (1) · Dr Rachel Farrell (1) · Emmanuel Cuny, Professor (1)
PMID 41491634, PMID 12529557, PMID 15037681, PMID 16108461, PMID 19416339, PMID 24100132, PMID 24607242, PMID 24909743, PMID 25536218, PMID 25593079, PMID 28867665, PMID 30554828, PMID 32232101, PMID 33040610, PMID 34362453, PMID 34438333, PMID 34484101, PMID 35351020, PMID 36325678, PMID 42156830
R21HD123083 (1)